Compared with patients without outcome events, patients who experienced outcome events were older, had higher levels of SBP, and had a higher prevalence of hypertension, MetS, CHD, HF, and stroke, had a higher proportion of usage of insulin, RAAS inhibitors, had higher levels of WBC counts, neutrophil counts, monocyte counts, Scr, BUN, SUA, urinary protein, TC, TG, FBG, and HbA1c, and had lower levels of DBP, HGB, lymphocyte, eGFR, serum ALB, and HDL-C, and had a higher proportion of usage of metformin, SGLT2 inhibitors, DPP4 inhibitors, and GLP1-RAs. The gene discussed is SLC5A2; the disease is stroke disorder.